View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 6, 2019

AstraZeneca-Merck’s Lynparza approved in China for ovarian cancer

AstraZeneca and Merck (MSD) have received the National Medical Products Administration (NMPA) approval in China for Lynparza (olaparib) to treat advanced germline or somatic BRCA mutated (gBRCAm or sBRCAm) ovarian cancer in adults.

AstraZeneca and Merck (MSD) have received the National Medical Products Administration (NMPA) approval in China for Lynparza (olaparib) to treat advanced germline or somatic BRCA mutated (gBRCAm or sBRCAm) ovarian cancer in adults.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The indication is for first-line maintenance therapy in newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer patients who have a complete or partial response to first-line platinum-based chemotherapy.

Lynparza inhibits DNA damage response (DDR) in tumours with a homologous recombination repair (HRR) deficiency. AstraZeneca and MSD partnered in 2017 to co-develop and co-commercialise the drug.

The drug holds approval in 65 countries to treat platinum-sensitive relapsed ovarian cancer, irrespective of BRCA status, with authorisation in 44 countries for treating certain germline BRCA-mutated breast cancer.

NMPA approval comes from data gathered from the Phase III SOLO-1 clinical trial, where the drug led to a 70% decrease in the risk of disease progression or death, compared to placebo.

During the study, 60% of participants treated with the drug were progression-free at three years versus 27% of those on placebo.

The trial assessed the safety and efficacy of 300mg twice-daily dose of the drug in a total of 391 patients.

The primary endpoint of the study was progression-free survival (PFS), while secondary endpoints included time to second disease progression or death, overall survival and time to first subsequent therapy.

Safety analysis revealed a profile consistent with previous trials. The most common adverse events were nausea, fatigue, vomiting, anaemia and diarrhoea.

AstraZeneca Oncology business unit executive vice-president Dave Fredrickson said: “This approval marks a new era for women with BRCA-mutated advanced ovarian cancer in China, where the prevalence of BRCA mutations in advanced disease is higher than the international average.

“Currently, 70% of women relapse within three years of initial treatment, representing the highest reoccurrence rate among gynaecological cancers worldwide. The progression-free survival benefit of Lynparza observed in SOLO-1 is a significant step towards helping these women achieve long-term remission.”

Lynparza secured approval in Europe and Japan to treat BRCA mutated advanced ovarian cancer in June.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology